Follow
Pascal Benkert
Pascal Benkert
University Hospital Basel
Verified email at usb.ch
Title
Cited by
Cited by
Year
Toward the estimation of the absolute quality of individual protein structure models
P Benkert, M Biasini, T Schwede
Bioinformatics 27 (3), 343-350, 2011
25012011
Protein structure homology modeling using SWISS-MODEL workspace
L Bordoli, F Kiefer, K Arnold, P Benkert, J Battey, T Schwede
Nature protocols 4 (1), 1-13, 2009
14672009
QMEAN: A comprehensive scoring function for model quality assessment
P Benkert, SCE Tosatto, D Schomburg
Proteins: Structure, Function, and Bioinformatics 71 (1), 261-277, 2008
11942008
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ...
Annals of neurology 81 (6), 857-870, 2017
9432017
QMEAN server for protein model quality estimation
P Benkert, M Künzli, T Schwede
Nucleic acids research 37 (suppl_2), W510-W514, 2009
9392009
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
C Barro, P Benkert, G Disanto, C Tsagkas, M Amann, Y Naegelin, ...
Brain 141 (8), 2382-2391, 2018
4322018
Serum neurofilament light levels in normal aging and their association with morphologic brain changes
M Khalil, L Pirpamer, E Hofer, MM Voortman, C Barro, D Leppert, ...
Nature communications 11 (1), 812, 2020
3722020
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ...
The Lancet Neurology 21 (3), 246-257, 2022
2362022
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors
D Wild, JB Bomanji, P Benkert, H Maecke, PJ Ell, JC Reubi, ME Caplin
Journal of Nuclear Medicine 54 (3), 364-372, 2013
2292013
QMEANclust: estimation of protein model quality by combining a composite scoring function with structural density information
P Benkert, T Schwede, SCE Tosatto
BMC structural biology 9, 1-17, 2009
1882009
Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation
D Conen, N Rodondi, A Müller, JH Beer, P Ammann, G Moschovitis, ...
Journal of the American College of Cardiology 73 (9), 989-999, 2019
1772019
Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years
E Cantó, C Barro, C Zhao, SJ Caillier, Z Michalak, R Bove, D Tomic, ...
JAMA neurology 76 (11), 1359-1366, 2019
1472019
Prodromal symptoms of multiple sclerosis in primary care
G Disanto, C Zecca, S MacLachlan, R Sacco, L Handunnetthi, UC Meier, ...
Annals of neurology 83 (6), 1162-1173, 2018
1242018
Heart failure therapy–induced early ST2 changes may offer long-term therapy guidance
T Breidthardt, C Balmelli, R Twerenbold, T Mosimann, J Espinola, P Haaf, ...
Journal of cardiac failure 19 (12), 821-828, 2013
1192013
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
B Delcoigne, A Manouchehrinia, C Barro, P Benkert, Z Michalak, ...
Neurology 94 (11), e1201-e1212, 2020
1132020
Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without coronavirus disease 2019
R Sutter, L Hert, GM De Marchis, R Twerenbold, L Kappos, Y Naegelin, ...
Annals of Neurology 89 (3), 610-616, 2021
792021
Global and local model quality estimation at CASP8 using the scoring functions QMEAN and QMEANclust
P Benkert, SCE Tosatto, T Schwede
Proteins: Structure, Function, and Bioinformatics 77 (S9), 173-180, 2009
772009
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
A Manouchehrinia, P Stridh, M Khademi, D Leppert, C Barro, Z Michalak, ...
Neurology 94 (23), e2457-e2467, 2020
692020
Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis
P Maggi, J Kuhle, S Schädelin, F Van Der Meer, M Weigel, R Galbusera, ...
Neurology 97 (6), e543-e553, 2021
662021
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis
J Lorscheider, P Benkert, C Lienert, P Hänni, T Derfuss, J Kuhle, ...
Multiple Sclerosis Journal 24 (6), 777-785, 2018
542018
The system can't perform the operation now. Try again later.
Articles 1–20